Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen.
Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Gastaut JA, Viens P, Maraninchi D, Olive D, Blaise D. Mohty M, et al. Among authors: coso d. Leukemia. 2003 Nov;17(11):2168-77. doi: 10.1038/sj.leu.2403105. Leukemia. 2003. PMID: 12931226 Clinical Trial.
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients.
Bouabdallah R, Stoppa AM, Rossi JF, Lepeu G, Coso D, Xerri L, Ladaique P, Chabannon C, Blaise D, Bardou VJ, Alzieu C, Gastaut JA, Maraninchi D. Bouabdallah R, et al. Among authors: coso d. Leukemia. 1999 Jun;13(6):950-6. doi: 10.1038/sj.leu.2401444. Leukemia. 1999. PMID: 10360385
Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): final analysis of survival in two consecutive ISC trials.
Bouabdallah R, Stoppa AM, Coso D, Bardou VJ, Blaise D, Chabannon C, Gastaut JA, Maraninchi D. Bouabdallah R, et al. Among authors: coso d. Ann Oncol. 2001 Apr;12(4):513-7. doi: 10.1023/a:1011160207382. Ann Oncol. 2001. PMID: 11398886 Free article.
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Chabannon C, Viens P, Maraninchi D, Blaise D. Mohty M, et al. Among authors: coso d. Blood. 2003 Jul 15;102(2):470-6. doi: 10.1182/blood-2002-12-3629. Epub 2003 Mar 20. Blood. 2003. PMID: 12649133 Free article.
Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen.
Faucher C, Mohty M, Vey N, Gaugler B, Bilger K, Moziconnacci MJ, Stoppa AM, Coso D, Ladaique P, Chabannon C, Reviron D, Maraninchi D, Gastaut JA, Olive D, Blaise D. Faucher C, et al. Among authors: coso d. Exp Hematol. 2003 Oct;31(10):873-80. doi: 10.1016/s0301-472x(03)00194-2. Exp Hematol. 2003. PMID: 14550802 Free article.
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C, Perreau V, Bilger K, Coso D, Stoppa AM, Tabrizi R, Gastaut JA, Michallet M, Maraninchi D, Blaise D. Mohty M, et al. Among authors: coso d. Bone Marrow Transplant. 2004 Jul;34(1):77-84. doi: 10.1038/sj.bmt.1704531. Bone Marrow Transplant. 2004. PMID: 15133485 Clinical Trial.
95 results